Your Article Summary
See Latest ArticlesKoreth J et al. - In a study to quantify relapse-free survival (RFS) and overall survival (OS) benefit of allogeneic stem cell transplantation (SCT) for acute myeloid leukemia (AML) in first complete remission (CR1) overall and also for good-, intermediate-, and poor-risk AML, it was concluded that compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and OS benefit for intermediate- and poor-risk AML, but not for good-risk AML in CR1.
Methods- The search used the combined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009.
- Prospective trials assigning adult pts with AML in CR1 to undergo allogeneic SCT vs nonallogeneic SCT treatment(s) based on donor availability and trials reporting RFS and/or OS outcomes on an intention-to-treat, donor vs no-donor basis were identified.
- The search identified 1712 articles.
- 2 reviewers independently extracted study characteristics, interventions, and outcomes.
- 24 trials and 6007 pts were analyzed (5951 pts in RFS analyses and 5606 pts in OS analyses); 3638 pts were analyzed by cytogenetic risk (547, 2499, and 592 with good-, intermediate-, and poor-risk AML, respectively).
- Interstudy heterogeneity was not significant.
- Fixed-effects meta-analysis was performed.
- Compared with nonallogeneic SCT, the HR of relapse or death with allogeneic SCT for AML in CR1 was 0.80.
- Significant RFS benefit of allogeneic SCT was documented for poor-risk and intermediate-risk AML but not for good-risk AML.
- The HR of death with allogeneic SCT for AML in CR1 was 0.90.
- Significant OS benefit with allogeneic SCT was documented for poor-risk and intermediate-risk AML, but not for good-risk AML.
Related Articles
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: Eighty-month follow-up
Bone Marrow Transplantation, 11/13/09
Relevance Score: 83%
Stem cell therapy for age-related retinal disease
Aging Health, 11/23/09
Relevance Score: 82%
Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia
Transplantation Proceedings, 11/23/09
Relevance Score: 82%
Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient
American Journal of Transplantation, 11/18/09
Relevance Score: 82%
Regulatory T Cell (Treg) Subsets Return in Patients with Refractory Lupus following Stem Cell Transplantation, and TGF-[beta]-Producing CD8+ Treg Cells Are Associated with Immunological Remission of Lupus
Journal of Immunology, 11/10/09
Relevance Score: 82%
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Can antigen-specific regulatory T cells protect against graft vs. host disease and spare anti-malignancy alloresponse
Haematologica, 12/18/09
Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy
Cancer Research, 12/18/09
Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
Annals of Hematology, 12/18/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)
Leukemia, 12/19/09
microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance
Genes, Chromosomes and Cancer, 12/19/09
Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia
Genes, Chromosomes and Cancer, 12/19/09